PatientsVille.com Logo

HEART RATE INCREASED and Trazodone

PatientsVille

HEART RATE INCREASED Symptoms and Causes

An arrhythmia is a problem with the rate or rhythm of your heartbeat. It means that your heart beats too quickly, too slowly, or with an irregular pattern. When the heart beats faster than normal, it is called tachycardia. When the heart beats too slowly, it is called bradycardia. The most common type of arrhythmia is atrial fibrillation, which causes an irregular and fast heart beat.

Many factors can affect your heart's rhythm, such as having had a heart attack, smoking, congenital heart defects, and stress. Some substances or medicines may also cause arrhythmias.

Symptoms of arrhythmias include

  • Fast or slow heart beat
  • Skipping beats
  • Lightheadedness or dizziness
  • Chest pain
  • Shortness of breath
  • Sweating

Your doctor can run tests to find out if you have an arrhythmia. Treatment to restore a normal heart rhythm may include medicines, an implantable cardioverter-defibrillator (ICD) or pacemaker, or sometimes surgery.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for HEART RATE INCREASED

HEART RATE INCREASED treatment research studies

Trazodone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Trazodone Side Effects

Completed Suicide (190)
Priapism (134)
Insomnia (129)
Dizziness (118)
Nausea (113)
Depression (109)
Respiratory Arrest (108)
Pain (102)
Headache (101)
Vomiting (94)
Cardiac Arrest (94)
Fatigue (91)
Anxiety (89)
Dyspnoea (89)
Confusional State (88)
Serotonin Syndrome (86)
Overdose (86)
Diarrhoea (80)
Suicide Attempt (79)
Asthenia (68)
Suicidal Ideation (34)
Fall (33)
Somnolence (30)
Feeling Abnormal (30)
Convulsion (29)
Arthralgia (28)
Toxicity To Various Agents (28)
Malaise (28)
Pain In Extremity (28)
Rash (28)
Weight Increased (27)
Hypotension (27)
Gait Disturbance (26)
Product Quality Issue (26)
Intentional Overdose (26)
Myalgia (26)
Constipation (25)
Tremor (24)
Loss Of Consciousness (23)
Condition Aggravated (23)
Muscle Spasms (22)
Back Pain (22)
Cardio-respiratory Arrest (22)
Electrocardiogram Qt Prolonged (21)
Pyrexia (21)
Palpitations (21)
Hallucination (20)
Amnesia (20)
Erectile Dysfunction (19)
Paraesthesia (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Yesterday, after taking Sam-e with Glucosamine. I got a pain between my shoulder blade, jaw pain, dizziness, sweating. felt like a heart attack. I did not go to the hospital because of the money needed. No ins

I took chapmix over 2 years ago and have been smoke free ever since, which I am very pleased about. However, I have had some issues with my heart, starting about a year ago with irregular, very rapid heartbeats. Finally I went through a whole

After using Clobetasol for a two week cycle, my doctor suggested I use it one day during the week, applying it twice that day. Since that time, I have experinced severe chest pain. I recently saw my doctor for heart attack symptoms before I reali

i had heart failure last august 2010, among other tablets i have been taking emconcor. i wonder whether these tablets are responsible for making my limbs feel weak, and lightheaded.

I HAD 1 SHOT OF THIS AND WITHIN 12 HOURS I WENT FROM A VERY NORMAL BLOOD PRESSURE TO WAKING AT 5 A.M. NEXT DAY WITH 198/110 AND 104 PULSE RATE. IT HAS CONTINUED ALL WEEK AFTER AND I'M NOW ON A BLOOD PRESSURE DRUG TO TRY AND CONTROL IT. EVEN WITH DR

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

I am real tired I've been on coreg about two weeks, I don't know if Ican keep taking it. I am so sleepy all the time don't want to do anything my chest hurts. Don't know what to do, if Idon't take it my heart want work right. JUST STUCK

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

fell dizziness and was admitted. Doc execute with dianostic including blood teat and heart check all. good. Doc make a decision by saying i'm getting Vertigo and treat with BETASERC. Below is the effect after 2 days take this medicine:- I was

HEART RATE INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Conditions: Delirium;   Agitation
Interventions: Drug: Risperidone;   Drug: Trazodone;   Drug: Placebo
Outcome Measures: The number of days patients are without delirium during the study period (delirium-free days);   Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU);   Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours;   The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day;   The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent;   The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication;   The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered;   The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered;   The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.;   The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days);   The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline);   The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score);   All-cause mortality and 28-day mortality
2 Unknown  A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Condition: Depression
Interventions: Drug: Trazodone;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale-17 score;   Changes in HAMA-14 score;   CGI-Severity of illness and CGI-Global improvement;   Changes in evaluation of sleep quality and sexual dysfunction;   Rate changes of responders/patients
3 Recruiting Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia
Condition: Insomnia
Interventions: Drug: Trazodone;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Change from Baseline in objective sleep duration at 9 months;   Change from Baseline in Subjective Severity of Sleep Disturbance & Subjective Sleep Duration at 9 months
4 Recruiting The Effects of Trazodone on Sleep Apnea Severity
Condition: Sleep Apnea, Obstructive
Interventions: Drug: Placebo pill;   Drug: Trazodone
Outcome Measures: Apnea-Hypopnea Index;   Arousal threshold
5 Unknown  Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations
Condition: Healthy
Interventions: Drug: Trazodone;   Drug: Quetiapine;   Drug: Pindolol;   Procedure: Blood Collection
Outcome Measure: Plasma levels of Medication
6 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
7 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
8 Recruiting Sequenced Therapies for Comorbid and Primary Insomnias
Conditions: Insomnia Comorbid to Psychiatric Disorder;   Primary Insomnia
Interventions: Behavioral: Behavioral Insomnia Therapy;   Drug: Zolpidem;   Drug: Trazodone;   Behavioral: Cognitive Therapy
Outcome Measure: Insomnia Severity Index- Change from Baseline (Remission)
9 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: Trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
10 Recruiting Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Condition: Lumbar Spinal Stenosis
Interventions: Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;   Procedure: Lumbar epidural injection;   Other: Joint Mobilizations (spine, sacroiliac, hip);   Other: Individualized exercises: clinical setting;   Other: Group Exercise: community setting
Outcome Measures: Swiss Spinal Stenosis Questionnaire Score;   Self Paced Walking Test
11 Recruiting The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
Condition: Chest Pain
Interventions: Drug: Marinol;   Drug: Placebo
Outcome Measures: Frequency of chest pain episodes;   Frequency of chest pain in treatment group vs baseline;   Intensity of chest pain episodes;   Sensory thresholds for first sensation;   Frequency of reactive esophageal contractions;   Amplitude of reactive esophageal contractions;   Area under the curve of reactive esophageal contractions;   Duration of chest pain episodes;   Sensory thresholds for discomfort;   Sensory thresholds for pain